Predictors of loss to follow-up among children on long-term antiretroviral therapy in Zambia (2003-2015).
ART
Adherence
HIV
Loss to follow-up
Pediatrics
Risk factors
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
15 Aug 2019
15 Aug 2019
Historique:
received:
17
07
2018
accepted:
26
07
2019
entrez:
17
8
2019
pubmed:
17
8
2019
medline:
5
11
2019
Statut:
epublish
Résumé
Retention in care is critical for children living with HIV taking antiretroviral therapy (ART). Loss to follow-up (LTFU) is high in HIV treatment programs in resource limited settings. We estimated the cumulative incidence of LTFU and identified associated risk factors among children on ART at Livingstone Central Hospital (LCH), Zambia. Using a retrospective cohort study design, we abstracted data from medical records of children who received ART between 2003 and 2015. Loss to follow-up was defined as no clinical and pharmacy contact for at least 90 days after the child missed their last scheduled clinical visit. Non-parametric competing risks models were used to estimate the cumulative incidence of death, LTFU and transfer. Cause-specific Cox regression was used to estimate the hazard ratios of the risk factors of LTFU. A total of 1039 children aged 0-15 years commenced ART at LCH between 2003 and 2015. Median duration of follow-up was 3.8 years (95% CI: 1.2-6.5), median age at ART initiation was 3.6 years (IQR: 1.3-8.6), 179 (17%) started treatment during their first year of life. At least 167 (16%) were LTFU and we traced 151 (90%). Of those we traced, 39 (26%) had died, 71 (47%) defaulted, 20 (13%) continued ART at other clinics and 21 (14%) continued treatment with gaps. The cumulative incidence of LTFU for the entire cohort was 2.7% (95% CI: 1.9-3.9) at 3 months, 4.1% (95% CI: 2.9-5.4) at 6 months and 14.1% (95% CI: 12.4-16.9) after 5 years on ART. Associated risk factors were: 1) non-disclosure of HIV status at baseline, aHR = 1.9 (1.2-2.9), 2) No phone ownership, aHR = 2.1 (1.6-2.9), 3) starting treatment between 2013 to 2015, aHR = 5.6 (2.2-14.1). Among the children LTFU mortality and default were substantially high. Children who started treatment in recent years (2013-2015) had the highest hazard of LTFU. Lack of access to a phone and non-disclosure of HIV-status to the index child was associated with higher hazards of LTFU. We recommend re-enforcement of client counselling and focused follow-up strategies using modern technology such as mobile phones as adjunct to current approaches.
Sections du résumé
BACKGROUND
BACKGROUND
Retention in care is critical for children living with HIV taking antiretroviral therapy (ART). Loss to follow-up (LTFU) is high in HIV treatment programs in resource limited settings. We estimated the cumulative incidence of LTFU and identified associated risk factors among children on ART at Livingstone Central Hospital (LCH), Zambia.
METHODS
METHODS
Using a retrospective cohort study design, we abstracted data from medical records of children who received ART between 2003 and 2015. Loss to follow-up was defined as no clinical and pharmacy contact for at least 90 days after the child missed their last scheduled clinical visit. Non-parametric competing risks models were used to estimate the cumulative incidence of death, LTFU and transfer. Cause-specific Cox regression was used to estimate the hazard ratios of the risk factors of LTFU.
RESULTS
RESULTS
A total of 1039 children aged 0-15 years commenced ART at LCH between 2003 and 2015. Median duration of follow-up was 3.8 years (95% CI: 1.2-6.5), median age at ART initiation was 3.6 years (IQR: 1.3-8.6), 179 (17%) started treatment during their first year of life. At least 167 (16%) were LTFU and we traced 151 (90%). Of those we traced, 39 (26%) had died, 71 (47%) defaulted, 20 (13%) continued ART at other clinics and 21 (14%) continued treatment with gaps. The cumulative incidence of LTFU for the entire cohort was 2.7% (95% CI: 1.9-3.9) at 3 months, 4.1% (95% CI: 2.9-5.4) at 6 months and 14.1% (95% CI: 12.4-16.9) after 5 years on ART. Associated risk factors were: 1) non-disclosure of HIV status at baseline, aHR = 1.9 (1.2-2.9), 2) No phone ownership, aHR = 2.1 (1.6-2.9), 3) starting treatment between 2013 to 2015, aHR = 5.6 (2.2-14.1).
CONCLUSION
CONCLUSIONS
Among the children LTFU mortality and default were substantially high. Children who started treatment in recent years (2013-2015) had the highest hazard of LTFU. Lack of access to a phone and non-disclosure of HIV-status to the index child was associated with higher hazards of LTFU. We recommend re-enforcement of client counselling and focused follow-up strategies using modern technology such as mobile phones as adjunct to current approaches.
Identifiants
pubmed: 31416432
doi: 10.1186/s12889-019-7374-0
pii: 10.1186/s12889-019-7374-0
pmc: PMC6694674
doi:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1120Références
JAMA. 2006 Aug 16;296(7):782-93
pubmed: 16905784
JAMA. 2007 Oct 24;298(16):1888-99
pubmed: 17954540
J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):202-8
pubmed: 19504732
J Acquir Immune Defic Syndr. 2010 Aug;54(5):524-32
pubmed: 20588185
Curr HIV/AIDS Rep. 2010 Nov;7(4):234-44
pubmed: 20820972
BMC Infect Dis. 2011 Jan 27;11:31
pubmed: 21272350
J Acquir Immune Defic Syndr. 2011 Jul 1;57(3):e40-6
pubmed: 21407085
Int J Epidemiol. 2012 Jun;41(3):861-70
pubmed: 22253319
J Int AIDS Soc. 2012 May 31;15(2):17381
pubmed: 22713255
PLoS One. 2013;8(3):e57907
pubmed: 23472118
PLoS Med. 2014 May 27;11(5):e1001649
pubmed: 24866209
AIDS Care. 2015;27(4):424-30
pubmed: 25397994
AIDS. 2015 Feb 20;29(4):493-502
pubmed: 25565496
J Acquir Immune Defic Syndr. 2015 Dec 15;70(5):e160-7
pubmed: 26218409
BMC Public Health. 2015 Oct 07;15:1028
pubmed: 26445104
J Int AIDS Soc. 2015 Dec 02;18(Suppl 6):20296
pubmed: 26639119
AIDS Care. 2016 Nov;28(11):1402-10
pubmed: 27160542
AIDS Care. 2017 Mar;29(3):378-386
pubmed: 27569657
Epidemiol Infect. 2017 Jan;145(1):170-180
pubmed: 27609130
MMWR Morb Mortal Wkly Rep. 2016 Nov 25;65(46):1285-1290
pubmed: 27880749
Nurs Res Pract. 2016;2016:9637587
pubmed: 28018673
Trop Med Int Health. 2017 Apr;22(4):375-387
pubmed: 28102610
PLoS Med. 2017 Apr 18;14(4):e1002278
pubmed: 28419097
PLoS One. 2018 Jun 6;13(6):e0197854
pubmed: 29874247
Clin Infect Dis. 2018 Nov 13;67(11):1643-1652
pubmed: 29889240